These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ; Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902 [TBL] [Abstract][Full Text] [Related]
28. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365 [TBL] [Abstract][Full Text] [Related]
29. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569 [TBL] [Abstract][Full Text] [Related]
30. Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports. van der Wilk BJ; Noordman BJ; Atmodimedjo PN; Dinjens WNM; Laheij RJF; Wagner A; Wijnhoven BPL; van Lanschot JJB Eur J Med Genet; 2020 Mar; 63(3):103840. PubMed ID: 31923587 [TBL] [Abstract][Full Text] [Related]
32. Pancreatic carcinoma surveillance in patients with familial melanoma. Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390 [TBL] [Abstract][Full Text] [Related]
33. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981 [TBL] [Abstract][Full Text] [Related]
34. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529 [TBL] [Abstract][Full Text] [Related]
35. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Pho L; Grossman D; Leachman SA Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187 [TBL] [Abstract][Full Text] [Related]
36. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978 [TBL] [Abstract][Full Text] [Related]
37. [Dysplastic nevi and the risk of melanoma: a guideline for patient care. Nederlandse Melanoom Werkgroep van de Vereniging voor Integrale Kankercentra]. Bergman W; van Voorst Vader PC; Ruiter DJ Ned Tijdschr Geneeskd; 1997 Oct; 141(42):2010-4. PubMed ID: 9550752 [TBL] [Abstract][Full Text] [Related]
38. The atypical-mole syndrome and predisposition to melanoma. Wachsmuth RC; Harland M; Bishop JA N Engl J Med; 1998 Jul; 339(5):348-9. PubMed ID: 9696648 [No Abstract] [Full Text] [Related]
39. CDKN2A mutation and deletion status in thin and thick primary melanoma. Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737 [TBL] [Abstract][Full Text] [Related]
40. Reply to: "The absence of multiple atypical nevi in germline CDKN2A mutations". Soura E; Stratigos AJ; Tsao H J Am Acad Dermatol; 2016 Oct; 75(4):e159. PubMed ID: 27646764 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]